Printer Friendly

United States : LICENSE agreement with Mount Sinai for Kiacta in sarcoidosis declared by Auven Therapeutics, Bellus Health.

Auven Therapeutics and Bellus Health have declared that Auven has signed a license agreement with the Icahn School of Medicine at Mount Sinai in New York, under which the company gains rights to develop Kiacta (eprodisate) as a treatment for chronic sarcoidosis.

Auven plans to perform a Phase II (proof-of-concept) clinical trial to assess KIACTA's effectiveness and safety to deal with certain medical manifestations of sarcoidosis. Kiacta is intended at dealing the disease process (that is pathophysiology) in sarcoidosis patients.

Auven thinks to confirm a study protocol by mid-year and expects that the trial will begin dosing patients in the fourth quarter of 2014. The Phase II trial is likely to be finished within about 18 months of the time the first patient is enrolled.

The idea to use Kiacta as a treatment for chronic sarcoidosis was developed by Dr Adam S Morgenthau, assistant professor of Medicine at the Icahn School of Medicine at Mount Sinai.

Auven Therapeutics co-founder and managing general partner Dr Peter B Corr mentioned that there is no cure for sarcoidosis, and treatment options are limited and can have serious adverse effects.

Dr Corr added, "Obtaining the rights to move KIACTA into a second indication further expands its commercial potential and may help patients with this sometimes debilitating chronic disease .

Kiacta is an orally bioavailable small molecule, currently being investigated in a Phase III pivotal study in patients with Amyloidosis, an orphan indication that results from long-standing inflammatory conditions.

Auven Therapeutics purchased worldwide rights connected to Kiacta from Bellus Health in 2010 and assumed control of the Kiacta development program and related activities, including the Phase III clinical study in Amyloidosis.

The agreement was discussed through Mount Sinai Innovation Partners which assists the real-world application and commercialization of Mount Sinai discoveries and the development of research partnerships with industry.

2014 Al Bawaba ( Provided by , an company
COPYRIGHT 2014 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:May 6, 2014
Previous Article:United States : GE CAPITAL launches new funding plan for commercial buyers of equipment.
Next Article:United States : MOC with Fujairah signed by Abu Dhabi Airports.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters